Text Size:AAA

BRAF Targeted Therapy

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
- Targeted Therapy for Kidney Cancer
- Targeted Therapy for Liver Cancer
- Colorectal Cancer Targeted Therapy
- What is Targeted Therapy for Cancer
- Targeted Therapy for Leukemia
- Targeted Therapy for Pancreatic Cancer
- Prostate Cancer Targeted Therapy
- Targeted Therapy for Ovarian Cancer
- Melanoma Targeted Therapy
- Targeted Therapy for Lung Cancer
- Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
- EGFR Targeted Therapy for Breast Cancer
- EGFR Targeted Therapy for Colorectal Cancer
- EGFR Targeted Therapy for Head and Neck Cancer
- EGFR Targeted Therapy for Non-Small-Cell Lung Cancer
- EGFR Targeted Therapy for Ovarian Cancer
- EGFR Targeted Therapy for Pancreatic Cancer
HER2 Targeted Therapy
- HER2 Targeted Therapy for Breast Cancer
- HER2 Targeted Therapy for Colorectal Cancer
- Her2 targeted therapy for Ovarian cancer
VEGF Targeted Therapy
- VEGF Targeted Therapy for Breast Cancer
- VEGF Targeted Therapy for Lung Cancer
- VEGF Targeted Therapy for Prostate Cancer
- VEGF Targeted Therapy for Colorectal Cancer
BRAF Targeted Therapy
- BRAF Targeted Therapy for Melanoma
- BRAF Targeted Therapy for Lung Cancer
ALK Targeted Therapy
- ALK Targeted Therapy for Lung Cancer
- ALK Targeted Therapy for Anaplastic Large Cell Lymphoma
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
- Targeted Therapy Drugs: Elotuzumab
- Targeted Therapy Drugs: Necitumumab
- Targeted Therapy Drugs: Daratumumab
- Targeted Therapy Drugs: Ramucirumab
- Targeted Therapy Drugs: Trastuzumab
- Targeted Therapy Drugs: Vemurafenib
- Targeted Therapy Drugs: Crizotinib
- The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work
Immunotherapy
Cancer Immunotherapy
Immune checkpoint

BRAF Targeted Therapy: Introduction

BRAF belongs to a family of serine-threonine protein kinases that includes ARAF, BRAF, and CRAF (RAF1). RAF kinases are central mediators in the MAP kinase signaling cascade and exert their effect predominantly through phosphorylation and activation of MEK. This occurs following the dimerization (hetero- or homo-) of the RAF molecules. As part of the MAP kinase pathway, RAF is involved in many cellular processes, including cell proliferation, differentiation, and transcriptional regulation.

BRAF Targeted Therapy: Melanoma

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors.

BRAF Targeted Therapy: Lung Cancer

Somatic activating BRAF mutations were first described by Davies et al. in 2002. Genomic DNA from 545 cancer cell lines and the corresponding matched lymphoblastoid cell lines from the same individuals were screened for sequence variants through the coding exons and intron-exon junctions of the BRAF gene. They reported an incidence of 8% across all cancers (43/545) and 3% in lung cancer (all adenocarcinomas) (4/131) . All BRAF somatic mutations found in the cancer lines were in exons 11 and 15. RAS and BRAF mutations usually occur in the same cancer types, but these mutations are found in a mutually exclusive fashion.

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”